Table 1.
Comparison of patients included and excluded in the two analysis cohorts based on availability of 6-month or 12-month CD4+ cell result
| 6 month cohort |
12 month cohort |
|||||
|---|---|---|---|---|---|---|
| Included (N = 24,366) | Excluded (N = 6,085) | P | Included (N = 17,920) | Excluded (N = 5,420) | P | |
| Age, median (Q1, Q3) | 35 (30, 41) | 35 (30, 41) | <0.01+ | 35 (30, 42) | 35 (30, 41) | <0.01+ |
| Female, n (%) | 15,086 (61.9%) | 3,702 (60.8%) | 0.12* | 11,212 (62.6%) | 3,328 (61.4%) | 0.12* |
| Body Mass Index | ||||||
| Female, median kg/m2 (Q1, Q3) | 19.5 (17.8, 21.4) | 19.3 (17.6, 21.2) | 0.01+ | 19.5 (17.8, 21.5) | 19.3 (17.6, 21.1) | <0.01+ |
| Male, median kg/m2 (Q1, Q3) | 20.4 (18.3, 22.9) | 20.2 (18.1, 22.8) | <0.01+ | 20.3 (18.3, 22.9) | 20.2 (18.0, 22.7) | <0.01+ |
| CD4+ count at baseline, median cells/μL (Q1, Q3) | 132 (70, 198) | 132 (67, 201) | 0.69+ | 130 (69, 195) | 129 (67, 198) | 0.78+ |
| ≥ 400 cells/μL, n (%) | 511 (2.1%) | 169 (2.8%) | <0.01* | 341 (1.9%) | 133 (2.5%) | <0.01* |
| 300–399 cells/μL, n (%) | 1,456 (6.0%) | 373 (6.1%) | 1,000 (5.6%) | 343 (6.3%) | ||
| 200–299 cells/μL, n (%) | 3,987 (16.4%) | 1,019 (16.7%) | 2,865 (16.0%) | 860 (15.9%) | ||
| 100–199 cells/μL, n (%) | 9,441 (38.7%) | 2,232 (36.7%) | 6,984 (39.0%) | 1,988 (36.7%) | ||
| < 100 cells/μL | 8,971 (36.8%) | 2,292 (37.7%) | 6,730 (37.6%) | 2,096 (38.7%) | ||
| Hemoglobin, median g/dL (Q1, Q3) | 10.9 (9.6, 12.3) | 10.9 (9.4, 12.3) | <0.01+ | 10.9 (9.6, 12.3) | 10.8 (9.4, 12.2) | <0.01+ |
| >10.0 g/dL, n (%) | 15,249 (69.3%) | 3,580 (66.6%) | <0.01* | 11,025 (69.6%) | 3,207 (66.2%) | <0.01* |
| 8.0 – 10.0 g/dL, n (%) | 5,076 (23.1%) | 1,321 (24.6%) | 3,666 (23.2%) | 1,200 (24.8%) | ||
| < 8.0 g/dL, n (%) | 1,686 (7.7%) | 478 (8.9%) | 1,139 (7.2%) | 435 (9.0%) | ||
| Tuberculosis at enrollment, n (%) | 3,268 (13.4%) | 866 (14.2%) | 0.09* | 2,360 (13.2%) | 718 (13.2%) | 0.88* |
| WHO Stage | ||||||
| I/II, n (%) | 8,102 (33.4%) | 1,743 (28.9%) | <0.01* | 5,939 (33.3%) | 1,530 (28.4%) | <0.01* |
| III, n (%) | 14,116 (58.2%) | 3,683 (61.0%) | 10,422 (58.4%) | 3,300 (61.2%) | ||
| IV, n (%) | 2,053 (8.5%) | 612 (10.1%) | 1,489 (8.3%) | 558 (10.4%) | ||
| Regimen | ||||||
| ZDV + 3TC + NVP, n (%) | 11,458 (47.2%) | 2,665 (43.9%) | <0.01* | 9,088 (50.9%) | 2,617 (48.4%) | 0.02* |
| ZDV + 3TC + EFV, n (%) | 942 (3.9%) | 232 (3.8%) | 676 (3.8%) | 200 (3.7%) | ||
| D4T + 3TC + NVP, n (%) | 9,302 (38.3%) | 2,443 (40.3%) | 7,125 (39.9%) | 2,284 (42.2%) | ||
| D4T + 3TC + EFV, n (%) | 1,367 (5.6%) | 386 (6.4%) | 972 (5.4%) | 307 (5.7%) | ||
| TDF + FTC + NVP, n (%) | 446 (1.8%) | 123 (2.0%) | 0 (0.0%) | 1 (0.0%) | ||
| TDF + FTC + EFV, n (%) | 784 (3.2%) | 215 (3.5%) | 10 (0.1%) | 3 (0.1%) | ||
| Adherence according to medication possession ratio | ||||||
| ≥ 95%, n (%) | 17,716 (72.7%) | 3,918 (64.4%) | <0.01* | 11,594 (64.7%) | 2,994 (55.2%) | <0.01* |
| 80% – 94%, n (%) | 4,609 (18.9%) | 1,281 (21.1%) | 4,957 (27.7%) | 1,743 (32.2%) | ||
| < 80%, n (%) | 2,041 (8.4%) | 886 (14.6%) | 1,369 (7.6%) | 683 (12.6%) | ||
*
Chi-square test, + Wilcoxon rank sum test
ZDV = zidovudine, D4T = stavudine, 3TC = lamivudine, NVP = nevirapine, EFV = efavirenz, TDF = tenofovir, FTC = emtricitabine